Why cure, why now?
Why cure, why now?
复制标题
DOI：
10.1136/medethics-2015-103113
复制
发表时间：
2017-02
影响因子：
4.1
通讯作者：
Kuritzkes DR
中科院分区：
文献类型：
--
作者：
Kuritzkes DR
联合抗逆转录病毒疗法 (cART) 在预防人类免疫缺陷病毒 (HIV) 感染引起的发病和死亡方面非常有效，但不能根除该病毒。因此，cART 必须终生施用。最近的进展刺激了治愈艾滋病毒感染的研究。正在研究的方法包括造血干细胞移植、潜伏再激活剂、基于免疫的疗法和基于细胞的疗法。这些方法中的每一种都带有潜在风险，必须根据安全有效的 cART 的可用性进行权衡。平衡这项研究的风险和收益给潜在的研究参与者、临床医生和研究人员带来了独特的挑战。
Combination antiretroviral therapy (cART) is highly effective at preventing morbidity and mortality due to infection with human immunodeficiency virus (HIV), but does not eradicate the virus. Consequently, cART must be administered life-long. Recent progress has stimulated research towards a cure of HIV infection. Approaches under investigation include hematopoietic stem cell transplantation, latency reactivating agents, immune based therapies, and cell-based therapies. Each of these approaches carries potential risks that must be weighed against the availability of safe and effective cART. Balancing the risks and benefits of this research poses unique challenges to potential study participants, clinicians and investigators.